Medgenics(Regs) Share Discussion Threads

[sicilian_kan] 23/6/2010 08:35

Fine. This is not a trader's stock, given its share structure, but the rewards are there for all to see, looking at the rises since 08 in both MEDG and MEDU.

[themoneymonster2] 23/6/2010 08:31

Dealing online is not currently available for the stock you have selected. Please Contact Us if you want to deal by telephone.

That's the message you get. I don't want anymore if I can't sell them online as you could get caught out when the herd want to sell.

[sicilian_kan] 23/6/2010 08:30

TDW let me buy, but if you need to buy on the phone, really what is the difference. £18 or so instead of £10? Or just put a fill or kill in online.

[themoneymonster2] 23/6/2010 08:26

Problem is, so many brokers won't let you buy them at all. I hold some and Barcs won't let me buy anymore or sell the ones I have got without ringing them up.

[sicilian_kan] 23/6/2010 08:25

This is an announcement to everyone! Those of you who are buying MEDU can now get 3.5x the number of shares of the same nominal value by buying MEDG. And they are over time convertable to MEDU too. It really does show how few shareholders read ADVFN or properly research their company.

[sicilian_kan] 23/6/2010 08:14

lol, this is just insane, MEDU at 28.5p mid, MEDG still at 8p.

[sicilian_kan] 23/6/2010 08:07

MEDG at 8p, MEDU at 26.5p !

[sicilian_kan] 23/6/2010 07:57

Come on MEDG, surely it is your turn now! Let's catch up with MEDU's 22.5p please!!

[Sorry for the emotional rant]

[sicilian_kan] 23/6/2010 07:52

This is outstanding news. There is so much more here than I thought there would be at this stage:

1. Patient recruitment has been exceptionally quick.
2. There is already evidence of proof of concept for the multiple use of biopumps.
3. They have already used the remote site Biopump processing centre

[sicilian_kan] 23/6/2010 07:48

RNS Number : 9877N Medgenics Inc 22 June 2010

Medgenics, Inc.

('Medgenics' or the 'Company')

Higher Dose EPO Biopumps Working in Patients

Misgav, Israel and London, UK -22 June 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is pleased to announce that the first new patients have now successfully commenced their treatment using biopumps producing middle dose levels of EPO in the Company's ongoing Phase I/II clinical trials with EPODURE. The new patients were also the first to have their Biopumps prepared at a remote site (the GMP processing center in Jerusalem), transported in a sealed chamber and subsequently administered locally at a major teaching hospital in Tel Aviv - thus successfully demonstrating the concept of a regional Biopump processing center serving a local treatment center, which is important for the wider implementation planned in the future.

In the first part of the Company's Phase I/II clinical trial, completed in 2009 at the Hadassah Medical Center in Jerusalem, the equivalent of the lowest recommended dose for EPO (20 IU/kg/day) was prepared at the local GMP center and administered in 6 of the patients treated and one patient was treated with the middle recommended dose (40 IU/kg/day). The biopumps produced EPO continuously in all the patients, elevating or maintaining the haemoglobin levels in many, even with the lowest EPO dose, with most continuing for the 6 month duration of the trial and one for more than 20 months.

This second part of the trial is being conducted at the Tel Aviv Medical Center, and is aimed at treating new patients with the medium and higher continuous doses to confirm that haemoglobin will be maintained or elevated over the period of the trial at higher dosage levels of EPO delivery. Demonstrating elevation of the haemoglobin level and its maintenance within the normal therapeutic range are primary objectives of this trial.

In this new stage of the continuing Phase I/II clinical trial, sufficient EPODURE biopumps will be administered to each patient to provide 40 IU/kg/day. Two weeks ago, the team conducting the trial at Tel Aviv Medical Center successfully harvested micro-organs from the first two new patients entering the study and processed them to become EPODURE biopumps. These biopumps produced sufficient EPO per day that only 3 or 4 biopumps were necessary in each patient, and these were administered to them on June 17.

The treatment of these new patients is possible as a result of the recently announced, successful fundraising rounds. The Company is now delivering on its plan to move forward with these trials, which have already demonstrated safety and proof of concept of the EPODURE biopump, and now aim to show a trend of greater haemoglobin responses with the higher doses administered. Following the implantation, the EPO measurements from the post-implant blood samples have confirmed a significant rise in serum EPO levels, demonstrating that the biopumps are efficiently delivering the protein in these patients. In the previous part of this trial, confirmed EPO production in situ was followed by an elevation of haemoglobin levels within the ensuing months and the Company is confident that this will also happen in this higher dose stage of the trial.

Dr. Andrew Pearlman, CEO of Medgenics commented: "We are very pleased that the first patients in the new part of our study have now commenced their treatment. We are particularly impressed with the potency of the EPODURE biopumps from these patients, which has enabled them to receive the medium dose using only a few biopump units, and with their successful preparation at a remote site Biopump processing center, establishing a model for wider future implementation. We now look forward to monitoring the haemoglobin response in these patients, while recruiting additional patients to the trial in the coming months. We are optimistic that this higher dose will confirm that the middle dose biopumps work well and that the therapeutic response is dose dependent and without adverse effects. As this is an open trial, we look forward to keeping investors updated as we treat additional patients and review the ongoing trial data."

[ihavenoclue] 09/6/2010 15:38

sicilian_kan - 9 Jun'10 - 12:02 - 123 of 126


That usually happens when they are either (a) short of stock (when buying) or (b) unwilling to take stock on (when selling). Are they phone only for both or was it a dummy buy or sell you did?

================================

sell ? Don't be daft !! I bought MEDG the other day, when MEDU went skyward, and had no problem.

Just tried a top up and it is phone only ... so I didn't bother.

Tick ups .. let's say to 20p ... another 46 required !!

[sicilian_kan] 09/6/2010 14:08

There's tick up number two of the day. Now how many more do we need :-)

[themoneymonster2] 09/6/2010 12:47

Guys are you sure, that these two stocks are worth the same as there is a big difference between 8.5p and 22.5p!

[sicilian_kan] 09/6/2010 12:02

That usually happens when they are either (a) short of stock (when buying) or (b) unwilling to take stock on (when selling). Are they phone only for both or was it a dummy buy or sell you did?

[themoneymonster2] 09/6/2010 12:00

IHNC, MEDU was tipped by red hot penny shares on Friday.

[ihavenoclue] 09/6/2010 11:58

Strange ... this has now gone Phone Only with Barclays ...

[ihavenoclue] 09/6/2010 11:52

True ... still curious what caused the strong rise in MEDU yesterday a day after the non-event RNS

[sicilian_kan] 09/6/2010 11:49

lol...it's a start in the right direction :-)

[ihavenoclue] 09/6/2010 11:44

I agree ... lots of them needed at 0.25p a time LOL

[sicilian_kan] 09/6/2010 11:37

And there's the first MEDG tick up. Hopefully many more to come to catch up with MEDU.

[sicilian_kan] 09/6/2010 07:50

So MEDG has a share price mid of 8p and MEDU has a share price mid of 26.5p. They are worth the same amount of money and MEDG shares can usually be converted to MEDU in any event, after a year. MEDG, at the moment, is the bargain of the century.

[ihavenoclue] 07/6/2010 21:49

sicilian_kan - 7 Jun'10 - 17:40 - 112 of 113


True, well it was the only rational reason I could think of. Interesting that MEDU's share price held up near 20p despite the RNS at the end of lunch.

-----------------------------------

Yup I agree on that point ... I wonder if this rises to join it or it drops to join this sub 10p ?

[sicilian_kan] 07/6/2010 19:53

I've seen the RHPS article. There are a couple of interesting new bits in there:

1. They state that the hemophilia partner Medgenics has is likely to be Bayer or Bristol-Myers.

2. They also state that "Last year Bristol-Myers struck a $535m licensing deal with ZymoGenetics for a relatively minor potential improvement to the efficacy of hepatitis C injections. But the Biopump has the potential to make not marginal improvements to standard drug therapy, but transform it altogether".

Interestingly hemophilia is only the third in line in the pipeline, with 11 major conditions being potential candidates for the Biopump.